agomelatine citric acid | 1403960-81-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: agomelatine citric acid
• 英文别名: N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide citric acid；N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide citrate；2-hydroxypropane-1,2,3-tricarboxylic acid;N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
• CAS: 1403960-81-5
• 化学式: C₆H₈O₇*C₁₅H₁₇NO₂
• 分子量: 435.431
• InChiKey: JPAYITIGCPEZCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  171
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  阿戈美拉汀 、 柠檬酸 在 乙醚 作用下， 以 丙酮 为溶剂， 2.0~123.5 ℃ 、2.0 MPa 条件下， 反应 69.0h， 生成 agomelatine citric acid
  参考文献：
  名称：

  PHARMACEUTICALLY ACCEPTABLE COCRYSTALS OF N-[2-(7-METHOXYL-1-NAPHTYL)ETHYL]ACETAMIDE AND METHODS OF THEIR PREPARATION

  摘要：

  本发明涉及阿戈美拉汀（I）的新型固态形式，具体而言是其新型药用可接受的共晶体，以及其制备方法。本发明获得了三种药用可接受的（I）的共晶体，其物理化学特性适合药物开发。

  公开号：

  US20140051887A1

文献信息

• CO-CRYSTALS OF AGOMELATINE, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Letellier Philippe

  公开号：US20120316245A1

  公开（公告）日：2012-12-13

  New co-crystal of agomelatine composed of: agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide of formula (I) and an organic acid. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.

  新的阿戈美拉汀共晶体由阿戈美拉汀或式（I）中的N-[2-（7-甲氧基-1-萘基）乙基]乙酰胺和有机酸组成。含有该物质的药物产品对治疗褪黑激素系统失调具有有用作用。
• Co-crystals of agomelatine with co-crystal-formers
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2551257A1

  公开（公告）日：2013-01-30

  The present invention relates to co-crystals of agomelatine and co-crystal-formers, processes for preparation of the same and their use as medicament or in pharmaceutical formulations, more particularly for the treatment of depression.

  本发明涉及阿戈美拉汀和共晶形成剂的共晶体，其制备过程以及它们作为药物或药物配方的用途，更具体地用于治疗抑郁症。
• [EN] PHARMACEUTICALLY ACCEPTABLE COCRYSTALS OF N-[2-(7-METHOXY-1-NAPHTYL)ETHYL]ACETAMIDE AND METHODS OF THEIR PREPARATION<br/>[FR] CO-CRISTAUX DE N-[2-(7-MÉTHOXY-1-NAPHTYL)ÉTHYL]ACÉTAMIDE PHARMACEUTIQUEMENT ACCEPTABLES ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：ZENTIVA KS

  公开号：WO2012146371A1

  公开（公告）日：2012-11-01

  The present invention relates to novel solid forms of agomelatine (I), specifically novel pharmaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that have physicochemical properties acceptable for pharmaceutical development were obtained.

  本发明涉及阿戈美拉汀（I）的新型固态形式，具体为其新型药物可接受的共晶体，以及制备它们的方法。获得了三种药物可接受的（I）共晶体，其物理化学性质适合于药物开发。
• Pharmaceutically acceptable cocrystals of N-[2-(7-methoxyl-1-naphtyl)ethyl]acetamide and methods of their preparation
  申请人：Miller Gary James

  公开号：US08927771B2

  公开（公告）日：2015-01-06

  The present invention relates to novel solid forms of agomelatine (I), specifically novel phaamaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that have physico-chemical properties acceptable for pharmaceutical development were obtained.

  本发明涉及一种阿戈美拉汀（I）的新型固态形式，具体是其新型药用可接受共晶体，以及制备它们的方法。获得了三种药用可接受的（I）共晶体，其物理化学性质适合制药开发。
• Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation
  申请人：Zentiva, k.s.

  公开号：EP2517700A1

  公开（公告）日：2012-10-31

  The present invention relates to novel solid forms of agomelatine (I), specifically novel pharmaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that have physicochemical properties acceptable for pharmaceutical development were obtained.

  本发明涉及阿戈美拉汀（I）的新型固体形式，特别是其新型药学上可接受的共晶体，以及制备它们的方法。本发明获得了(I)的三种药学上可接受的共晶体，其理化性质可用于药物开发。